WO2006116107A3 - Immunoliposome composition for targeting to a her2 cell receptor - Google Patents

Immunoliposome composition for targeting to a her2 cell receptor Download PDF

Info

Publication number
WO2006116107A3
WO2006116107A3 PCT/US2006/015122 US2006015122W WO2006116107A3 WO 2006116107 A3 WO2006116107 A3 WO 2006116107A3 US 2006015122 W US2006015122 W US 2006015122W WO 2006116107 A3 WO2006116107 A3 WO 2006116107A3
Authority
WO
WIPO (PCT)
Prior art keywords
targeting
immunoliposome
cell receptor
her2
her2 cell
Prior art date
Application number
PCT/US2006/015122
Other languages
French (fr)
Other versions
WO2006116107A2 (en
Inventor
Kristen Hjortsvang
Luke Guo
Francis M P Wong
Azar Najafi
Anthony Huang
Robert Abra
Laura Kelley
Original Assignee
Alza Corp
Kristen Hjortsvang
Luke Guo
Francis M P Wong
Azar Najafi
Anthony Huang
Robert Abra
Laura Kelley
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alza Corp, Kristen Hjortsvang, Luke Guo, Francis M P Wong, Azar Najafi, Anthony Huang, Robert Abra, Laura Kelley filed Critical Alza Corp
Priority to CA002605560A priority Critical patent/CA2605560A1/en
Priority to MX2007013200A priority patent/MX2007013200A/en
Priority to BRPI0610026-0A priority patent/BRPI0610026A2/en
Priority to JP2008507922A priority patent/JP2008536944A/en
Priority to AU2006239973A priority patent/AU2006239973A1/en
Priority to EP06750988A priority patent/EP1871424A2/en
Publication of WO2006116107A2 publication Critical patent/WO2006116107A2/en
Priority to IL186700A priority patent/IL186700A0/en
Publication of WO2006116107A3 publication Critical patent/WO2006116107A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A61K47/6913—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome the liposome being modified on its surface by an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

An immunoliposome composition comprised of liposomes bearing a ligand for targeting to cells expressing a growth factor receptor, such as HER2, is described. Binding of the immunoliposome to HER2-expressing cells results in internalization of the immunoliposome for cytoplasmic delivery of an entrapped drug.
PCT/US2006/015122 2005-04-22 2006-04-20 Immunoliposome composition for targeting to a her2 cell receptor WO2006116107A2 (en)

Priority Applications (7)

Application Number Priority Date Filing Date Title
CA002605560A CA2605560A1 (en) 2005-04-22 2006-04-20 Immunoliposome composition for targeting to a her2 cell receptor
MX2007013200A MX2007013200A (en) 2005-04-22 2006-04-20 Immunoliposome composition for targeting to a her2 cell receptor.
BRPI0610026-0A BRPI0610026A2 (en) 2005-04-22 2006-04-20 immunoliposome composition for targeting a her2 cell receptor
JP2008507922A JP2008536944A (en) 2005-04-22 2006-04-20 Immunoliposome composition for targeting the HER2 cell receptor
AU2006239973A AU2006239973A1 (en) 2005-04-22 2006-04-20 Immunoliposome composition for targeting to a HER2 cell receptor
EP06750988A EP1871424A2 (en) 2005-04-22 2006-04-20 Immunoliposome composition for targeting to a her2 cell receptor
IL186700A IL186700A0 (en) 2005-04-22 2007-10-16 Immunoliposome composition for targeting to a her2 cell receptor

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US67402905P 2005-04-22 2005-04-22
US60/674,029 2005-04-22
US73666905P 2005-11-14 2005-11-14
US60/736,669 2005-11-14

Publications (2)

Publication Number Publication Date
WO2006116107A2 WO2006116107A2 (en) 2006-11-02
WO2006116107A3 true WO2006116107A3 (en) 2008-07-24

Family

ID=37027489

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/015122 WO2006116107A2 (en) 2005-04-22 2006-04-20 Immunoliposome composition for targeting to a her2 cell receptor

Country Status (11)

Country Link
US (1) US20060269542A1 (en)
EP (1) EP1871424A2 (en)
JP (1) JP2008536944A (en)
KR (1) KR20080002995A (en)
AU (1) AU2006239973A1 (en)
BR (1) BRPI0610026A2 (en)
CA (1) CA2605560A1 (en)
IL (1) IL186700A0 (en)
MX (1) MX2007013200A (en)
TW (1) TW200719917A (en)
WO (1) WO2006116107A2 (en)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004003144A2 (en) * 2002-07-01 2004-01-08 Human Genome Sciences, Inc. Antibodies that specifically bind to reg iv
WO2008141276A1 (en) * 2007-05-11 2008-11-20 Centocor, Inc. Anti-alpha-v immunoliposome composition, methods and uses
EP2177230A4 (en) * 2007-08-09 2011-04-27 Daiichi Sankyo Co Ltd Immunoliposome inducing apoptosis into cell expressing death domain-containing receptor
WO2010051502A2 (en) * 2008-10-31 2010-05-06 Biogen Idec Ma Inc. Light targeting molecules and uses thereof
JP5299922B2 (en) * 2009-02-04 2013-09-25 国立大学法人大阪大学 HB-EGF binding protein complex
WO2011017297A2 (en) * 2009-08-03 2011-02-10 The University Of North Carolina At Chapel Hill Biodegradable delivery system complexes for the delivery of bioactive compounds
CA2791278C (en) 2010-02-25 2015-11-24 The Johns Hopkins University Sustained delivery of therapeutic agents to an eye compartment
EP3539988A3 (en) 2010-05-27 2019-12-04 Genmab A/S Monoclonal antibodies against her2
WO2011147982A2 (en) 2010-05-27 2011-12-01 Genmab A/S Monoclonal antibodies against her2 epitope
US20130150563A1 (en) * 2010-07-09 2013-06-13 Jv Bio Srl Lipid-conjugated antibodies
EP2648738A2 (en) 2010-12-06 2013-10-16 Merrimack Pharmaceuticals, Inc. Dosage and administration for preventing cardiotoxicity in treatment with erbb2-targeted immunoliposomes comprising anthracyclin chemotherapeutic agents
AU2012245116A1 (en) 2011-04-20 2013-11-07 Genmab A/S Bispecific antibodies against HER2 and CD3
CA2832387A1 (en) 2011-04-20 2012-10-26 Genmab A/S Bispecifc antibodies against her2
TW201330874A (en) 2011-12-12 2013-08-01 Kyowa Hakko Kirin Co Ltd Lipid nano particles comprising combination of cationic lipid
US9839616B2 (en) 2011-12-12 2017-12-12 Kyowa Hakko Kirin Co., Ltd. Lipid nano particles comprising cationic lipid for drug delivery system
EP2849728A1 (en) 2012-05-04 2015-03-25 The Johns Hopkins University Lipid-based drug carriers for rapid penetration through mucus linings
TW201726599A (en) 2012-07-06 2017-08-01 協和醱酵麒麟有限公司 Cationic lipid
WO2014046630A1 (en) 2012-09-19 2014-03-27 Keskin, Dilek Tumor targeted liposomal drug delivery system
KR20150091116A (en) 2012-12-03 2015-08-07 메리맥 파마슈티컬즈, 인크. Combination therapy for treating her2-positive cancers
WO2014124006A1 (en) 2013-02-05 2014-08-14 The Johns Hopkins University Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof
JP6294456B2 (en) * 2013-03-13 2018-03-14 マリンクロッド エルエルシー Modified docetaxel liposome formulation
AU2016211696B2 (en) 2015-01-27 2018-05-10 The Johns Hopkins University Hypotonic hydrogel formulations for enhanced transport of active agents at mucosal surfaces
CN114469872A (en) 2015-11-12 2022-05-13 灰色视觉公司 Aggregate microparticles for therapy
CA3009131A1 (en) 2015-12-25 2017-06-29 Kyowa Hakko Kirin Co., Ltd. Compounds as cationic lipids and their use in nucleic acid delivery compositions
CA3032810A1 (en) * 2016-08-02 2018-02-08 Curirx Inc. Methods for the preparation of liposomes
EP3595636A4 (en) * 2017-03-16 2021-01-13 Children's Medical Center Corporation Engineered liposomes as cancer-targeted therapeutics
US11160870B2 (en) 2017-05-10 2021-11-02 Graybug Vision, Inc. Extended release microparticles and suspensions thereof for medical therapy
WO2019027055A1 (en) 2017-08-04 2019-02-07 協和発酵キリン株式会社 Nucleic-acid-containing lipid nanoparticles
WO2023054243A1 (en) * 2021-09-30 2023-04-06 日油株式会社 Lipid nanoparticles having cell directivity

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999058694A1 (en) * 1998-05-12 1999-11-18 The Regents Of The University Of California Methods of forming protein-linked lipidic microparticles, and compositions thereof

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260203A (en) * 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
WO1989006692A1 (en) * 1988-01-12 1989-07-27 Genentech, Inc. Method of treating tumor cells by inhibiting growth factor receptor function
US6214388B1 (en) * 1994-11-09 2001-04-10 The Regents Of The University Of California Immunoliposomes that optimize internalization into target cells
AU6113396A (en) * 1995-06-14 1997-01-15 Regents Of The University Of California, The Novel high affinity human antibodies to tumor antigens
US6056973A (en) * 1996-10-11 2000-05-02 Sequus Pharmaceuticals, Inc. Therapeutic liposome composition and method of preparation
US6794128B2 (en) * 1998-04-24 2004-09-21 The Regents Of The University Of California Methods of selecting internalizing antibodies

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999058694A1 (en) * 1998-05-12 1999-11-18 The Regents Of The University Of California Methods of forming protein-linked lipidic microparticles, and compositions thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
KIRPOTIN D ET AL: "STERICALLY STABILIZED ANTI-HER2 IMMUNOLIPOSOMES: DESIGN AND TARGETING TO HUMAN BREAST CANCER CELLS IN VITRO", BIOCHEMISTRY, AMERICAN CHEMICAL SOCIETY. EASTON, PA, US, vol. 36, no. 1, 1997, pages 66 - 75, XP002927736, ISSN: 0006-2960 *
NIELSEN U B ET AL: "Therapeutic efficacy of anti-ErbB2 immunoliposomes targeted by a phage antibody selected for cellular endocytosis", BIOCHIMICA ET BIOPHYSICA ACTA. MOLECULAR CELL RESEARCH, ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, NL, vol. 1591, no. 1-3, 19 August 2002 (2002-08-19), pages 109 - 118, XP004377273, ISSN: 0167-4889 *
PARK J W ET AL: "Tumor targeting using anti-her2 immunoliposomes", JOURNAL OF CONTROLLED RELEASE, ELSEVIER, AMSTERDAM, NL, vol. 74, no. 1-3, 6 July 2001 (2001-07-06), pages 95 - 113, XP004297516, ISSN: 0168-3659 *

Also Published As

Publication number Publication date
IL186700A0 (en) 2008-02-09
US20060269542A1 (en) 2006-11-30
CA2605560A1 (en) 2006-11-02
MX2007013200A (en) 2008-03-24
TW200719917A (en) 2007-06-01
WO2006116107A2 (en) 2006-11-02
EP1871424A2 (en) 2008-01-02
KR20080002995A (en) 2008-01-04
AU2006239973A1 (en) 2006-11-02
BRPI0610026A2 (en) 2010-05-18
JP2008536944A (en) 2008-09-11

Similar Documents

Publication Publication Date Title
WO2006116107A3 (en) Immunoliposome composition for targeting to a her2 cell receptor
WO2009138473A3 (en) Intracellular antibody delivery
WO2009065022A3 (en) Low density lipoprotein receptor-mediated sirna delivery
WO2008079973A3 (en) Egfr binding peptides and uses thereof
WO2009143412A3 (en) Polymeric systems containing intracellular releasable disulfide linker for the delivery of oligonucleotides
WO2010040772A3 (en) Targeting construct comprising anti-polymer antibody and liposomes or microvesicles binding to the same
WO2005087926A3 (en) Multiple promoter expression cassettes for simultaneous delivery of rnai agents
WO2005111238A3 (en) Aptamer-mediated intracellular delivery of therapeutic oligonucleotides
WO2006032958A3 (en) Composition in micro-pellets with controlled release physiologically active substance, procedure for their preparation and use in the zootechenical sector
WO2011075516A3 (en) Active scaffolds for on-demand drug and cell delivery
WO2011160093A3 (en) Methods and systems for modulating hormones and related methods, agents and compositions
WO2006113679A3 (en) Delivery of sirna by neutral lipid compositions
WO2009134952A3 (en) Potent conjugates and hydrophilic linkers
WO2008147816A3 (en) Compositions and methods for the display of proteins on the surface of bacteria and their derived vesicles and uses thereof
WO2012056110A3 (en) Cell culture material based on microbial cellulose
EP2462924A3 (en) Improvements in or relating to amphoteric liposomes.
MX2013005046A (en) Cytotoxic agents comprising new ansamitocin derivatives.
WO2007082693A3 (en) Improved enzyme formulations for animal feed
WO2007121318A3 (en) Formulations for delivering insulin
WO2009140432A3 (en) Micelles for intracellular delivery of therapeutic agents
WO2007019845A8 (en) Method for encapsulating therapeutic substances in cells
WO2010045598A3 (en) Psma binding ligand-linker conjugates and methods for using
MX2019003005A (en) Lipid containing formulations.
WO2009099641A3 (en) Stabilized protein compositions
EP2308514A3 (en) Conjugates for targeted drug delivery across the blood-brain barrier

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 562030

Country of ref document: NZ

WWE Wipo information: entry into national phase

Ref document number: 2006239973

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 3857/KOLNP/2007

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 186700

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2605560

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2008507922

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: MX/a/2007/013200

Country of ref document: MX

Ref document number: 2006750988

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2006239973

Country of ref document: AU

Date of ref document: 20060420

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020077027088

Country of ref document: KR

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: PI0610026

Country of ref document: BR

Kind code of ref document: A2